NASDAQ:CLGN

CollPlant Biotechnologies Competitors

$14.45
+0.14 (+0.98 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.49
Now: $14.45
$14.45
50-Day Range
$11.00
MA: $13.30
$14.70
52-Week Range
$6.00
Now: $14.45
$24.26
Volume44,300 shs
Average Volume120,058 shs
Market Capitalization$81.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11

Competitors

CollPlant Biotechnologies (NASDAQ:CLGN) Vs. IVC, SMTI, LAKE, SRGA, SRGA, and CFMS

Should you be buying CLGN stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to CollPlant Biotechnologies, including Invacare (IVC), Sanara MedTech (SMTI), Lakeland Industries (LAKE), Surgalign (SRGA), Surgalign (SRGA), and Conformis (CFMS).

Invacare (NYSE:IVC) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Invacare and CollPlant Biotechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00103.00
CollPlant Biotechnologies00103.00

Invacare currently has a consensus target price of $17.00, suggesting a potential upside of 93.40%. CollPlant Biotechnologies has a consensus target price of $26.00, suggesting a potential upside of 79.93%. Given Invacare's higher possible upside, equities research analysts plainly believe Invacare is more favorable than CollPlant Biotechnologies.

Risk & Volatility

Invacare has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Institutional & Insider Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 15.7% of CollPlant Biotechnologies shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Invacare and CollPlant Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
CollPlant Biotechnologies-149.91%-116.41%-59.02%

Earnings and Valuation

This table compares Invacare and CollPlant Biotechnologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.33$-53,330,000.00($1.06)-8.29
CollPlant Biotechnologies$2.32 million35.32$-11,160,000.00($1.29)-11.20

CollPlant Biotechnologies has lower revenue, but higher earnings than Invacare. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Invacare, indicating that it is currently the more affordable of the two stocks.

Summary

Invacare beats CollPlant Biotechnologies on 9 of the 12 factors compared between the two stocks.

CollPlant Biotechnologies (NASDAQ:CLGN) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Institutional & Insider Ownership

15.7% of CollPlant Biotechnologies shares are held by institutional investors. 78.4% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for CollPlant Biotechnologies and Sanara MedTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CollPlant Biotechnologies00103.00
Sanara MedTech0000N/A

CollPlant Biotechnologies currently has a consensus price target of $26.00, indicating a potential upside of 79.93%. Given CollPlant Biotechnologies' higher probable upside, research analysts clearly believe CollPlant Biotechnologies is more favorable than Sanara MedTech.

Profitability

This table compares CollPlant Biotechnologies and Sanara MedTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CollPlant Biotechnologies-149.91%-116.41%-59.02%
Sanara MedTech-39.58%-175.36%-55.40%

Valuation and Earnings

This table compares CollPlant Biotechnologies and Sanara MedTech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CollPlant Biotechnologies$2.32 million35.32$-11,160,000.00($1.29)-11.20
Sanara MedTech$11.77 million19.58$-2,810,000.00N/AN/A

Sanara MedTech has higher revenue and earnings than CollPlant Biotechnologies.

Volatility & Risk

CollPlant Biotechnologies has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

CollPlant Biotechnologies (NASDAQ:CLGN) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Volatility & Risk

CollPlant Biotechnologies has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Lakeland Industries has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for CollPlant Biotechnologies and Lakeland Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CollPlant Biotechnologies00103.00
Lakeland Industries00203.00

CollPlant Biotechnologies presently has a consensus price target of $26.00, suggesting a potential upside of 79.93%. Lakeland Industries has a consensus price target of $37.00, suggesting a potential upside of 35.23%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Lakeland Industries.

Profitability

This table compares CollPlant Biotechnologies and Lakeland Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CollPlant Biotechnologies-149.91%-116.41%-59.02%
Lakeland Industries18.93%28.75%24.67%

Earnings & Valuation

This table compares CollPlant Biotechnologies and Lakeland Industries' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CollPlant Biotechnologies$2.32 million35.32$-11,160,000.00($1.29)-11.20
Lakeland Industries$107.81 million2.04$3.28 million$0.4560.80

Lakeland Industries has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Lakeland Industries, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 70.8% of Lakeland Industries shares are owned by institutional investors. 4.9% of Lakeland Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Lakeland Industries beats CollPlant Biotechnologies on 10 of the 13 factors compared between the two stocks.

CollPlant Biotechnologies (NASDAQ:CLGN) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Earnings & Valuation

This table compares CollPlant Biotechnologies and Surgalign's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CollPlant Biotechnologies$2.32 million35.32$-11,160,000.00($1.29)-11.20
Surgalign$308.38 million0.68$-211,640,000.00($0.16)-11.81

CollPlant Biotechnologies has higher earnings, but lower revenue than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 53.5% of Surgalign shares are held by institutional investors. 3.7% of Surgalign shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares CollPlant Biotechnologies and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CollPlant Biotechnologies-149.91%-116.41%-59.02%
Surgalign-56.07%-101.34%-18.44%

Volatility & Risk

CollPlant Biotechnologies has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CollPlant Biotechnologies and Surgalign, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CollPlant Biotechnologies00103.00
Surgalign00403.00

CollPlant Biotechnologies presently has a consensus target price of $26.00, suggesting a potential upside of 79.93%. Surgalign has a consensus target price of $4.3333, suggesting a potential upside of 129.28%. Given Surgalign's higher probable upside, analysts plainly believe Surgalign is more favorable than CollPlant Biotechnologies.

Summary

Surgalign beats CollPlant Biotechnologies on 11 of the 13 factors compared between the two stocks.

CollPlant Biotechnologies (NASDAQ:CLGN) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Volatility and Risk

CollPlant Biotechnologies has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Valuation & Earnings

This table compares CollPlant Biotechnologies and Surgalign's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CollPlant Biotechnologies$2.32 million35.32$-11,160,000.00($1.29)-11.20
Surgalign$308.38 million0.68$-211,640,000.00($0.16)-11.81

CollPlant Biotechnologies has higher earnings, but lower revenue than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CollPlant Biotechnologies and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CollPlant Biotechnologies-149.91%-116.41%-59.02%
Surgalign-56.07%-101.34%-18.44%

Insider and Institutional Ownership

15.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 53.5% of Surgalign shares are owned by institutional investors. 3.7% of Surgalign shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for CollPlant Biotechnologies and Surgalign, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CollPlant Biotechnologies00103.00
Surgalign00403.00

CollPlant Biotechnologies presently has a consensus target price of $26.00, indicating a potential upside of 79.93%. Surgalign has a consensus target price of $4.3333, indicating a potential upside of 129.28%. Given Surgalign's higher probable upside, analysts plainly believe Surgalign is more favorable than CollPlant Biotechnologies.

Summary

Surgalign beats CollPlant Biotechnologies on 11 of the 13 factors compared between the two stocks.

CollPlant Biotechnologies (NASDAQ:CLGN) and Conformis (NASDAQ:CFMS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Earnings and Valuation

This table compares CollPlant Biotechnologies and Conformis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CollPlant Biotechnologies$2.32 million35.32$-11,160,000.00($1.29)-11.20
Conformis$77.43 million2.00$-28,480,000.00($0.44)-1.92

CollPlant Biotechnologies has higher earnings, but lower revenue than Conformis. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Conformis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

CollPlant Biotechnologies has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Conformis has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for CollPlant Biotechnologies and Conformis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CollPlant Biotechnologies00103.00
Conformis01302.75

CollPlant Biotechnologies presently has a consensus target price of $26.00, indicating a potential upside of 79.93%. Conformis has a consensus target price of $2.3333, indicating a potential upside of 175.51%. Given Conformis' higher possible upside, analysts clearly believe Conformis is more favorable than CollPlant Biotechnologies.

Profitability

This table compares CollPlant Biotechnologies and Conformis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CollPlant Biotechnologies-149.91%-116.41%-59.02%
Conformis-32.11%-174.01%-32.59%

Institutional & Insider Ownership

15.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 30.2% of Conformis shares are held by institutional investors. 3.2% of Conformis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Conformis beats CollPlant Biotechnologies on 10 of the 14 factors compared between the two stocks.


CollPlant Biotechnologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Invacare logo
IVC
Invacare
1.6$8.79+1.1%$302.59 million$927.96 million-7.15
SMTI
Sanara MedTech
0.8$30.25+1.3%$230.41 million$11.77 million-23.45Decrease in Short Interest
Gap Down
Lakeland Industries logo
LAKE
Lakeland Industries
1.8$27.36+3.4%$219.43 million$107.81 million7.77Earnings Announcement
Analyst Report
Gap Down
Surgalign logo
SRGA
Surgalign
1.7$1.89+2.1%$208.41 million$308.38 million-1.05Increase in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$1.89+2.1%$208.41 million$308.38 million-1.05Increase in Short Interest
Conformis logo
CFMS
Conformis
1.3$0.85+2.1%$154.50 million$77.43 million-2.49
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.84+1.6%$84.81 million$4.87 million-1.46
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.08+4.6%$52.70 million$1.41 million-0.17
AHPI
Allied Healthcare Products
0.5$4.48+3.3%$17.97 million$31.89 million0.00
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.85+0.0%$11.39 million$530,000.00-1.42Decrease in Short Interest
Gap Up
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.